Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, lists possible policy changes that would strengthen the safety net.
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, lists possible policy changes that would strengthen the safety net.
Transcript
What policy changes are you looking to see that would strength the safety net?
One of the big changes we would like to see is spreading the out-of-pocket cost for Medicare patients throughout the benefit year rather than having it all hit in the beginning of the year. I think a lot of patients really could probably afford their out of pocket cost if they could spread it out. So, we’re hoping that there will be some attention towards that. We would also like to see at least one highly effective drug for each indication being placed on a non-specialty tier. So, having a copay rather than a coinsurance for at least one of the innovators specialty drugs for each indication. Then, of course, the third and one you hear more often is putting an out-of-pocket limit on the catastrophic phase in Medicare. We think that that would be helpful but it’s not gonna affect that many people. There’s only about 2% of Medicare beneficiaries who reach the catastrophic threshold.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More